US waives tariffs on certain speciality drugs from 20 countries, including India - Moneycontrol.com
29 Sept, 00:07 IST · Plays out within days · 1 source
The US waived tariffs on certain speciality drugs from 20 countries including India, which helps Indian drug exporters like Sun Pharma by keeping US sales cheap and hurts no one directly.
Key facts
What the reporting establishes, before any reading of it.
- US waives tariffs for 20 countries including India
- Covers certain speciality drugs
- Waiver precedes threatened 100% pharma tariff
- Named beneficiaries: Sun Pharma, Dr Reddy, Cipla
How the news spreads
Step by step — from the first companies it hits to whole sectors.
Who it hits first
- The United States waived import tariffs on certain speciality drugs shipped from 20 countries, including India, just ahead of a threatened 100% tariff on pharmaceuticals.
- Indian makers of speciality and generic drugs — led by Sun Pharmaceutical (India's largest drug maker), Dr Reddy's Laboratories, and Cipla — can keep selling into the US without a sudden cost jump.
- The relief is narrow (only certain speciality drugs) and comes with the bigger tariff threat still hanging, so the gain is real but capped.
Who may gain
- Sun Pharmaceutical (India's largest drug maker) — biggest US speciality and generic sales base to protect.
- Dr Reddy's Laboratories (generic and speciality drug maker) — keeps US pricing intact.
- Cipla (respiratory and generic drug maker) — same US cost relief.
- Divi's Laboratories (bulk-drug ingredient maker) — supplies all three named exporters, so steadier US orders flow upstream.
- Laurus Labs (drug-ingredient and contract maker) — supplies Dr Reddy's and Cipla.
- Biocon (biologics maker) — speciality-biologic sales get tariff shelter, though weak profits limit the cheer.
Along the supply chain
Downstream
Downstream, US distributors and patients see no price jump on the covered speciality drugs, so demand stays steady rather than shifting to other countries' suppliers.
Upstream
Upstream makers of drug ingredients benefit second-hand: Divi's Laboratories supplies Sun Pharma, Dr Reddy's, and Cipla, and Laurus Labs supplies Dr Reddy's and Cipla, so steadier US formulation sales support their order books.
Where demand moves
Business
US buyers keep ordering Indian speciality drugs at tariff-free prices instead of cutting back or switching suppliers, so export volumes and margins for Sun Pharma, Dr Reddy's, and Cipla hold up.
Capital
Investors re-rate US-exposed pharma shares as the near-term tariff shock is removed, pulling money back into large exporters and their ingredient suppliers.
How it spreads across sectors
Healthcare
Positive but narrow — US-facing drug exporters and their ingredient suppliers gain, while domestic hospitals and labs feel nothing.
When it plays out
Immediate
In 1-7 days, US-exposed pharma shares likely bounce as the tariff threat lifts and exporters confirm coverage.
Medium term
In 1-6 months, the benefit lasts only if the waiver holds and the broader tariff stays away; any widening of US drug tariffs reverses it.
Short term
In 1-4 weeks, gains settle as investors check which speciality drugs are covered and watch the threatened 100% tariff's next move.